Literature DB >> 29098700

Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin.

John O Miners1, Attarat Pattanawongsa1, Andrew Rowland1.   

Abstract

Entities:  

Keywords:  UDP-glucuronosyltransferase; canagliflozin; drug-drug interaction; enzyme inhibition

Mesh：

Substances：

Year:  2017        PMID： 29098700      PMCID： PMC5777442          DOI： 10.1111/bcp.13443

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions.

Authors:  Attarat Pattanawongsa; Nuy Chau; Andrew Rowland; John O Miners
Journal:  Drug Metab Dispos       Date:  2015-07-15       Impact factor: 3.922

2.  Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.

Authors:  John O Miners; Nuy Chau; Andrew Rowland; Kushari Burns; Ross A McKinnon; Peter I Mackenzie; Geoffrey T Tucker; Kathleen M Knights; Ganessan Kichenadasse
Journal:  Biochem Pharmacol       Date:  2017-01-06       Impact factor: 5.858

3.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

4.  Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin.

Authors:  John O Miners; Attarat Pattanawongsa; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335

5.  In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.

Authors:  Rao N V S Mamidi; Shannon Dallas; Carlo Sensenhauser; Heng Keang Lim; Ellen Scheers; Peter Verboven; Filip Cuyckens; Laurent Leclercq; David C Evans; Michael F Kelley; Mark D Johnson; Jan Snoeys
Journal:  Br J Clin Pharmacol       Date:  2016-12-20       Impact factor: 4.335

6.  The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.

Authors:  Andrew Rowland; Kathleen M Knights; Peter I Mackenzie; John O Miners
Journal:  Drug Metab Dispos       Date:  2008-03-24       Impact factor: 3.922

7.  The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.

Authors:  John O Miners; Peter I Mackenzie; Kathleen M Knights
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

8.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971
  8 in total
  1 in total

1.  Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin.

Authors:  John O Miners; Attarat Pattanawongsa; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2017-11-03       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.